Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioNTech SE (BNTX)
Get information about the BioNTech Stock. Find more details on BNTX stock price to help you take informed decisions by going to one of the sections under this page - from BNTX Stock historical data, price charts and technical analysis to the balance sheet. Find BioNTech quotes in the main stock markets such as NASDAQ and Frankfurt, among others.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.80
90.88
52 wk Range
79.52
124.00
BNTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
85.8090.88
52 wk Range
79.52124.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BNTX Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
116.93
Upside
+36.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Holds more cash than debt on its balance sheet
Biontech Se receives Investment Bank Analyst Rating Update- Investing.com
Pro
Biontech Se receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biontech Se receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
14 Buy
7 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 116.93
(+36.19% Upside)
BioNTech SE SWOT Analysis
Oncology Ambitions | BioNTech aims for 10 new approvals by 2030, with promising results in lung and breast cancer trials showcasing its ambitious oncology pipeline |
Financial Fortitude | $18 billion cash reserves and positive cash flow provide BioNTech with stability and flexibility for R&D investments and strategic acquisitions |
Vaccine Legacy | COVID-19 vaccine business continues to generate substantial revenue, funding BioNTech's transition into a diversified biotechnology powerhouse |
Market Outlook | Analysts set price targets ranging from $125 to $130, reflecting cautious optimism about BioNTech's oncology potential and financial health |
BioNTech SE Earnings Call Summary for Q3/2026
- BioNTech Q3 2026 earnings beat estimates with $1.76 EPS vs. $0.78 forecast and $1.29B revenue vs. $1.05B; shares rose 2.81% premarket.
- Revenue declined YoY due to falling COVID-19 vaccine sales, but partnership income from Bristol Myers Squibb boosted results significantly.
- Company raised full-year 2026 revenue guidance midpoint to €1.7B-€1.9B; R&D spending up 20.9% as oncology pipeline advances.
- CEO Ugur Sahin to step down by Feb 2027, replaced by Guido Oelkers; founders remain involved as shareholders during transition.
- Management targets seven pivotal oncology studies by end-2026; gotistobart interim data expected before year-end, pumitamig Phase III in 2027.
Last Updated: 2026-11-03, 09:18 a/m
Read Full TranscriptEarnings
Latest Release
Nov 03, 2026
EPS / Forecast
1.76 / 0.78
Revenue / Forecast
1.29B / 1.05B
Compare BNTX to Peers and Sector
Metrics to compare | BNTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBNTXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.6x | −3.9x | −0.2x | |
PEG Ratio | 0.09 | 0.06 | 0.00 | |
Price/Book | 1.1x | 1.9x | 2.6x | |
Price / LTM Sales | 8.3x | 5.0x | 2.8x | |
Upside (Analyst Target) | 35.7% | 14.0% | 62.7% | |
Fair Value Upside | Unlock | −2.5% | 8.0% | Unlock |
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the BioNTech (BNTX) Stock Price Today?
The BioNTech stock price today is 85.86 USD.
What Stock Exchange Does BioNTech Trade On?
BioNTech is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for BioNTech?
The stock symbol for BioNTech is "BNTX."
What Is the BioNTech Market Cap?
As of today, BioNTech market cap is 22.49B USD.
What Is BioNTech's Earnings Per Share (TTM)?
The BioNTech EPS (TTM) is -6.67.
When Is the Next BioNTech Earnings Date?
BioNTech will release its next earnings report on Mar 02, 2027.
From a Technical Analysis Perspective, Is BNTX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has BioNTech Stock Split?
BioNTech has split 0 times.
How Many Employees Does BioNTech Have?
BioNTech has 7807 employees.
What is the current trading status of BioNTech (BNTX)?
As of Nov 06, 2026, BioNTech (BNTX) is trading at a price of 85.86 USD, with a previous close of 90.70 USD. The stock has fluctuated within a day range of 85.80 USD to 90.88 USD, while its 52-week range spans from 79.52 USD to 124.00 USD.
What Is BioNTech (BNTX) Price Target According to Analysts?
The average 12-month price target for BioNTech is 116.93 USD, with a high estimate of 145.00563063 USD and a low estimate of 76.42792793 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +36.19% Upside potential.
What Is the BNTX Premarket Price?
BNTX's last pre-market stock price is 91.03 USD. The pre-market share volume is 5,430.00, and the stock has decreased by 0.33, or 0.36%.
What Is the BNTX After Hours Price?
BNTX's last after hours stock price is 85.63 USD, the stock has decreased by -0.23, or -0.27%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.